Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis.

Matteo Santoni; Alessandro Conti; Sebastiano Buti; Melissa Bersanelli; Laura Foghini; Francesco Piva; Matteo Giulietti; Lukas Lusuardi; Nicola Battelli

doi:10.2217/imt-2018-0067

Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis.

Matteo Santoni, Alessandro Conti, Sebastiano Buti, Melissa Bersanelli, Laura Foghini, Francesco Piva, Matteo Giulietti, Lukas Lusuardi (Co-author), Nicola Battelli

Department of Urology and Andrology

Research output: Contribution to journal › Review article › peer-review

1 Citation (Web of Science)

Original language	English
Pages (from-to)	1303-1313
Journal	IMMUNOTHERAPY
Volume	10
Issue number	15
DOIs	https://doi.org/10.2217/imt-2018-0067
Publication status	Published - 2018

Keywords

METASTATIC UROTHELIAL CARCINOMA
NIVOLUMAB PLUS IPILIMUMAB
OPEN-LABEL
LUNG-CANCER
SINGLE-ARM
1ST-LINE TREATMENT
CLINICAL ACTIVITY
CHECKMATE 032
PEMBROLIZUMAB
MULTICENTER

Access to Document

10.2217/imt-2018-0067

Cite this

@article{9121e996f34343bfab519c71db1fa501,

title = "Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis.",

keywords = "METASTATIC UROTHELIAL CARCINOMA, NIVOLUMAB PLUS IPILIMUMAB, OPEN-LABEL, LUNG-CANCER, SINGLE-ARM, 1ST-LINE TREATMENT, CLINICAL ACTIVITY, CHECKMATE 032, PEMBROLIZUMAB, MULTICENTER",

author = "Matteo Santoni and Alessandro Conti and Sebastiano Buti and Melissa Bersanelli and Laura Foghini and Francesco Piva and Matteo Giulietti and Lukas Lusuardi and Nicola Battelli",

note = "Lusuardi: Paracelsus Med Univ Salzburg, Dept Urol & Androl, Salzburg, Austria",

year = "2018",

doi = "10.2217/imt-2018-0067",

language = "English",

volume = "10",

pages = "1303--1313",

journal = "IMMUNOTHERAPY",

issn = "1750-743X",

number = "15",

}

TY - JOUR

T1 - Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis.

AU - Santoni, Matteo

AU - Conti, Alessandro

AU - Buti, Sebastiano

AU - Bersanelli, Melissa

AU - Foghini, Laura

AU - Piva, Francesco

AU - Giulietti, Matteo

AU - Lusuardi, Lukas

AU - Battelli, Nicola

N1 - Lusuardi: Paracelsus Med Univ Salzburg, Dept Urol & Androl, Salzburg, Austria

PY - 2018

Y1 - 2018

KW - METASTATIC UROTHELIAL CARCINOMA

KW - NIVOLUMAB PLUS IPILIMUMAB

KW - OPEN-LABEL

KW - LUNG-CANCER

KW - SINGLE-ARM

KW - 1ST-LINE TREATMENT

KW - CLINICAL ACTIVITY

KW - CHECKMATE 032

KW - PEMBROLIZUMAB

KW - MULTICENTER

U2 - 10.2217/imt-2018-0067

DO - 10.2217/imt-2018-0067

M3 - Review article

C2 - 30474475

SN - 1750-743X

VL - 10

SP - 1303

EP - 1313

JO - IMMUNOTHERAPY

JF - IMMUNOTHERAPY

IS - 15

ER -